TY - JOUR
T1 - The Importance of Imaging in Radiation Oncology for National Clinical Trials Network Protocols
AU - FitzGerald, Thomas J.
AU - Bishop-Jodoin, Maryann
AU - Laurie, Fran
AU - O'Meara, Elizabeth
AU - Davis, Christine
AU - Bogart, Jeffrey
AU - Kalapurakal, John
AU - Siegel, Marilyn J.
AU - Chakravarthy, Bapsi
AU - Okunieff, Paul
AU - Haffty, Bruce
AU - Michalski, Jeff
AU - Ulin, Kenneth
AU - Followill, David S.
AU - Kry, Stephen
AU - Knopp, Michael
AU - Zhang, Jun
AU - Rosen, Don
AU - Rosen, Mark
AU - Xiao, Ying
AU - Schwartz, Lawrence
AU - Moni, Janaki
AU - Cicchetti, Maria Giulia
N1 - Funding Information:
Conflict of interest: T.J.F, D.S.F, S.K., M.K, M.R., and Y.X. report funding from the National Cancer Institute (grant no. CA 180803), during the study. S.K. reports grants from the National Cancer Institute during the conduct of the study.
Publisher Copyright:
© 2018
PY - 2018/11/15
Y1 - 2018/11/15
N2 - Imaging is essential in successfully executing radiation therapy (RT) in oncology clinical trials. As technically sophisticated diagnostic imaging and RT were incorporated into trials, quality assurance in the National Clinical Trials Network groups entered a new era promoting image acquisition and review. Most trials involving RT require pre- and post-therapy imaging for target validation and outcome assessment. The increasing real-time (before and during therapy) imaging and RT object reviews are to ensure compliance with trial objectives. Objects easily transmit digitally for review from anywhere in the world. Physician interpretation of imaging and image application to RT treatment plans is essential for optimal trial execution. Imaging and RT data sets are used to credential RT sites to confirm investigator and institutional ability to meet trial target volume delineation and delivery requirements. Real-time imaging and RT object reviews can be performed multiple times during a trial to assess response to therapy and application of RT objects. This process has matured into an effective data management mechanism. When necessary, site and study investigators review objects together through web media technologies to ensure the patient is enrolled on the appropriate trial and the intended RT is planned and executed in a trial-compliant manner. Real-time imaging review makes sure: (1) the patient is entered and eligible for the trial, (2) the patient meets trial-specific adaptive therapy requirements, if applicable, and (3) the intended RT is according to trial guidelines. This review ensures the study population is uniform and the results are believable and can be applied to clinical practice.
AB - Imaging is essential in successfully executing radiation therapy (RT) in oncology clinical trials. As technically sophisticated diagnostic imaging and RT were incorporated into trials, quality assurance in the National Clinical Trials Network groups entered a new era promoting image acquisition and review. Most trials involving RT require pre- and post-therapy imaging for target validation and outcome assessment. The increasing real-time (before and during therapy) imaging and RT object reviews are to ensure compliance with trial objectives. Objects easily transmit digitally for review from anywhere in the world. Physician interpretation of imaging and image application to RT treatment plans is essential for optimal trial execution. Imaging and RT data sets are used to credential RT sites to confirm investigator and institutional ability to meet trial target volume delineation and delivery requirements. Real-time imaging and RT object reviews can be performed multiple times during a trial to assess response to therapy and application of RT objects. This process has matured into an effective data management mechanism. When necessary, site and study investigators review objects together through web media technologies to ensure the patient is enrolled on the appropriate trial and the intended RT is planned and executed in a trial-compliant manner. Real-time imaging review makes sure: (1) the patient is entered and eligible for the trial, (2) the patient meets trial-specific adaptive therapy requirements, if applicable, and (3) the intended RT is according to trial guidelines. This review ensures the study population is uniform and the results are believable and can be applied to clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85054902078&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2018.08.039
DO - 10.1016/j.ijrobp.2018.08.039
M3 - Article
C2 - 30353882
AN - SCOPUS:85054902078
SN - 0360-3016
VL - 102
SP - 775
EP - 782
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 4
ER -